Related references
Note: Only part of the references are listed.Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors
Marzia Del Re et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
Zhu Zeng et al.
FRONTIERS IN ONCOLOGY (2021)
A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients
Guanghui Gao et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Current strategies for intratumoural immunotherapy-Beyond immune checkpoint inhibition
Jianda Yuan et al.
EUROPEAN JOURNAL OF CANCER (2021)
Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
Ho Jung An et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
Ye Wang et al.
FRONTIERS IN ONCOLOGY (2021)
MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma
Jiansheng Huang et al.
FEBS OPEN BIO (2020)
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma
Jing Quan Lim et al.
LEUKEMIA (2020)
eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA
Yu Wu et al.
BIOCHEMICAL JOURNAL (2020)
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
Shruthy Suresh et al.
NATURE CANCER (2020)
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Shunli Peng et al.
MOLECULAR CANCER (2019)
Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer
Yanhua Wu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement
Stefania Bellone et al.
CLINICAL CANCER RESEARCH (2018)
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
Adrien Costantini et al.
ONCOIMMUNOLOGY (2018)
Variant SNPs at the microRNA complementary site in the B7-H1 3'-untranslated region increase the risk of non-small cell lung cancer
Wenwen Du et al.
MOLECULAR MEDICINE REPORTS (2017)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)